stonks4u
Sign up free
NSPR logo

NSPR InspireMD, Inc.

NASDAQ Capital Market · Medical - Devices · Healthcare

$0.98
+0.14 (+16.94%)

InspireMD, Inc., an Israel-based medical technology company established in 2005, specializes in creating and commercializing advanced medical devices. Its core expertise lies in the proprietary MicroNet stent platform technology, engineered to address various vascular and coronary diseases. The company's offerings, distributed through a network of local partners, reach markets across Europe, Latin…

Market Cap: $46.01Mwww.inspiremd.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

100
100
Aug 17Aug 17

Quote

Day Range
$0.85 – $1.02
52-Week Range
$0.63 – $2.57
Volume
$437.9K
Market Cap
$46.01M
50-Day Avg
$0.73
200-Day Avg
$1.41
Prev Close
$0.84
Open
$0.85

Valuation & Ratios

P/E Ratio
-2.34
EPS
$-0.66
P/B Ratio
2.37
P/S Ratio
14.56
Debt/Equity
0.06
Current Ratio
5.74
Dividend Yield
+0.0%
Gross Margin
+29.5%

Returns & Efficiency

Return on Equity
-88.4%
Return on Assets
-70.3%
FCF Yield
-28.1%
EV/EBITDA
-2.59

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$8.98M$-48.79M$-0.76
2024$7.01M$-32.01M$-0.76
2023$6.21M$-19.92M$-0.82
2022$5.17M$-18.49M$-2.35
2021$4.50M$-14.92M$-2.03

Social Signal Score

50
5d
51
1 mentions
—
30d
50
1 mentions
—
60d
50
1 mentions
—
90d
50
1 mentions
—
news: 1

Earnings

6of 8 quarters beat consensus

Typical surprise +10.0% (median, so one quarter with a near-zero estimate can't distort it)

  • Mon, Aug 17$-0.17 vs $-0.20beat
  • Mon, May 4$-0.16 vs $-0.19beat
  • Wed, Mar 18$-0.14 vs $-0.22beat
  • Tue, Nov 4$-0.17 vs $-0.17beat
  • Mon, Aug 4$-0.26 vs $-0.24miss
  • Fri, May 9$-0.22 vs $-0.17miss

Estimates and results for NSPR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Insider trading

Open-market buys and sells by NSPR officers and directors.

Bought
$675k

19 trades

Sold
$289k

24 trades

  • Stuka Paulbought
    director·20,000 @ $0.88·$18k·May 27, 2026·filing
  • Gleason Shane Thomassold
    Chief Commercial Officer·22,778 @ $1.01·$23k·May 19, 2026·filing
  • Stuka Paulbought
    director·5,000 @ $1.15·$6k·May 14, 2026·filing
  • Stuka Paulbought
    director·10,000 @ $1.16·$12k·May 13, 2026·filing
  • Slosman Marvinbought
    director, officer: CEO and President·21,000 @ $1.20·$25k·May 12, 2026·filing
  • Stuka Paulbought
    director·10,000 @ $1.19·$12k·May 11, 2026·filing
  • Stuka Paulbought
    director·65,626 @ $1.16·$76k·May 8, 2026·filing
  • Ward Scott R.bought
    director·73,255 @ $1.15·$84k·May 7, 2026·filing

57 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.

Valuation

NSPRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsglobenewswire.com·5h ago·Neutral

    … Financial Results - Company to host investor conference call today, August 17 th , at 8:30am EDT - MIAMI, Aug. 17, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the three and six months ended June 30, 2026. Recent Business Highlights: Generated revenue of $1.8 million in the second quarter of 2026, in line with the second…

    View source ↗